UBS Upgrades Jazz Pharmaceuticals to Buy, Sets $307 Target
UBS has lifted Jazz Pharmaceuticals to Buy with a $307 price target, arguing that improving fundamentals and a stren...
Both funds offer diversification; index funds are passive and typically cheaper. This comparison highlights key differences to inform your choice.
24,304 articlesUBS has lifted Jazz Pharmaceuticals to Buy with a $307 price target, arguing that improving fundamentals and a stren...
April data show a split in new construction: multifamily projects surged while single-family starts declined, leaving...
Wall Street’s bearish take on Plug Power stock has critics unsure. This article builds a practical bull case, showing...
Looking to build retirement wealth with a focus on AI? This guide highlights three AI stocks worth holding until reti...
Eli Lilly has been a standout growth stock thanks to GLP-1 drug demand. Could a stock split be on the horizon? This g...
Texas Instruments is outperforming NVIDIA in 2026 as the chip landscape shifts from GPU hype to broad AI infrastructu...
A CNBC program features a tech CEO who says AI will replace junior staff and urges a tax on automation, triggering a ...
An insider move can send shockwaves through a stock, but it isn't a crystal ball. This guide explains what theFork CE...
Rocket Lab isn’t profitable yet, but the space company shows four clear catalysts for investors. Here are practical r...
Vanguard's dividend-growth ETF outpaced the Dividend Aristocrats ETF over the past decade, delivering higher returns ...
Investors chase the next big energy winner as AI drives data centers demand. Oklo presents a high-risk, high-puture o...
Jim Cramer says he is watching Marvell after Jensen Huang’s trillion-dollar endorsement, making the AI hardware name ...